Alicia Bailen

Malaga, AN, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia.

Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia.

Journal: Leukemia & lymphoma

Published: August 25, 2017

C3 glomerulonephritis associated with monoclonal gammopathy of renal significance: case report.

C3 glomerulonephritis associated with monoclonal gammopathy of renal significance: case report.

Journal: BMC nephrology

Published: February 22, 2017

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia.

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia.

Journal: European journal of haematology

Published: August 31, 2015

Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.

Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.

Journal: The Lancet. Haematology

Published: February 01, 2015

Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score.

Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score.

Journal: Leukemia research

Published: July 11, 2014

Results of allogeneic stem cell transplantation in the Spanish MDS registry: prognostic factors for low risk patients.

Results of allogeneic stem cell transplantation in the Spanish MDS registry: prognostic factors for low risk patients.

Journal: Leukemia research

Published: May 26, 2014

Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.

Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.

Journal: British journal of haematology

Published: December 20, 2013

Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review.

Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review.

Journal: European journal of haematology

Published: December 07, 2013

Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.

Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.

Journal: Leukemia research

Published: October 01, 2013

Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes.

Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes.

Journal: Leukemia & lymphoma

Published: August 20, 2013

Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome.

Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome.

Journal: Leukemia research

Published: November 09, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026